Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nelivaptan
- Development stage
- Discontinued
- Lead developer
- HMNC Brain Health
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Nelivaptan is a selective, orally active, non-peptide antagonist of the vasopressin V1b receptor. It was originally developed by Sanofi and later by HMNC Brain Health for the treatment of psychiatric disorders such as anxiety and depression. Nelivaptan acts by blocking the vasopressin V1b receptor (AVPR1B), which is implicated in stress response and affective behaviors. The drug advanced to phase II clinical trials for major depressive disorder but its development was previously halted by Sanofi-Aventis in 2008; it has since been revived and is currently under phase II development by HMNC Brain Health[1][2][3][4][5].
- Other names
- nelivaptan
02
Targets
AVPR1B (Vasopressin V1b Receptor)AVPR1A (Arginine vasopressin receptor 1A)AVPR2 (Arginine vasopressin V2 receptor)Oxytocin receptor
Beyond the preview
Go deeper on nelivaptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nelivaptan.